Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12090069 | 1.00 | CYP1A2 (0.52) | CYP1A2ADRA2ACHRNB4CHRNA3 | |
| SCHEMBL12089498 | 1.00 | CYP1A2 (0.52) | CYP1A2ADRA2ACHRNB4CHRNA3 | |
| SCHEMBL439594 | 0.93 | CYP1A2 (0.44) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL6960581 | 0.93 | CYP1A2 (0.44) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL8320293 | 0.93 | CYP1A2 (0.44) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL17834046 | 0.84 | — | — | |
| SCHEMBL21859507 | 0.84 | — | — | |
| SCHEMBL17834044 | 0.84 | — | — | |
| SCHEMBL21890124 | 0.83 | CYP1A2 (0.48) | CYP1A2ADRA2A | |
| SCHEMBL21983391 | 0.83 | CYP1A2 (0.48) | CYP1A2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023247595-A1 | PYRAZOLOPYRAZINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CAPELLA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CAPELLA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2022076831-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11242352-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-23 | — | — | US | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170174697-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-8450494-B2 | Disubstituted benzamide derivatives as glucokinase (GK) activators | CADILA HEALTHCARE LIMITED (IN) | 2013-05-28 | — | — | US | disclosed |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| US-20100055183-A1 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090258922-A1 | COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST | SHIONOGI & CO., LTD. | 2009-10-15 | — | — | US | disclosed |
| US-7534897-B2 | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7435729-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174697-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | CYP1A2 1573/4885ADRA2A 3492/4885CHRNB4 4425/4885 |
| US-20090258922-A1 | COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST | CYSLTR2, CYSLTR1, HRH2 | CYP1A2 749/4885ADRA2A 134/4885CHRNB4 1460/4885 |
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | TLR9, TLR7, TLR8 | CYP1A2 3926/4885ADRA2A 1706/4885CHRNB4 2772/4885 |
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CCNI, CYP2C19, PHB1 | CYP1A2 27/4885ADRA2A 2186/4885CHRNB4 4645/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | CYP1A2 1702/4885ADRA2A 154/4885CHRNB4 529/4885 |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | CYP1A2 1605/4885ADRA2A 3558/4885CHRNB4 4526/4885 |
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | CYP1A2 1947/4885ADRA2A 3698/4885CHRNB4 4433/4885 |
| US-20100055183-A1 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | IGFBP5, BMP2, HGF | CYP1A2 923/4885ADRA2A 3030/4885CHRNB4 4534/4885 |
| US-11242352-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | CYP1A2 1573/4885ADRA2A 3492/4885CHRNB4 4425/4885 |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CHEK1, CHEK2, BUB1B | CYP1A2 1822/4885ADRA2A 1170/4885CHRNB4 4548/4885 |
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | TLR9, TLR7, TLR8 | CYP1A2 3913/4885ADRA2A 1684/4885CHRNB4 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.